Lupin (LUPIN) — Financial Results

Lupin Limited delivered robust Q3 FY2026 results with total revenues of ₹7,168 crores, reflecting 24% YoY growth. EBITDA margins expanded significantly to 31.1%, up 681 bps YoY, while EBITDA grew 62% YoY to ₹2,210 crores. The US business achieved record sales of USD 350 million (46% growth), driven by Tolvaptan and the first biosimilar approval (Pegfilgrastim). India's prescription business grew 10.9% YoY with chronic therapies comprising 67% of the portfolio. Emerging markets surged 42% YoY, led by Brazil's 99% growth. Management raised FY2026 EBITDA margin guidance to 27-28% from 25-26%.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How does this financial results affect Lupin Limited's outlook?" "What did Lupin Limited announce on 17 February 2026?" "Is this positive or negative for LUPIN?"

Ask AI Free →

📊 More LUPIN filings

See all LUPIN filings →

🔥 Also filed on 17 February 2026

SBILIFE SBI Life Insurance Company Limited Corporate Action TATAPOWER Tata Power Company Limited Insider Trading TECHM Tech Mahindra Limited Corporate Action AXISBANK Axis Bank Limited Corporate Action DRREDDY Dr. Reddy's Laboratories Limited Corporate Action BAJAJFINSV Bajaj Finserv Limited Board Meeting

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.